New antibody and protein promise hope for Alzheimer’s sufferers

New antibody and protein promise hope for Alzheimer’s sufferers

Shared by:

Previously romanticised as the “The Long Goodbye”, Alzheimer’s disease is anything but. However, there is hope in two recent discoveries that could speed up the development of a cure.
14 Sep 2016 - General
The most common kind of dementia is Alzheimer’s disease, a disease that affects millions of people around the world and is considered on of the main leading causes of death, but scientists have been unable to reach consensus about the cause of the condition, and despite more than 400 drug trials, nothing has been shown to combat disease. Of course antibodies have better chances to prove efficacy like it did with other diseases such as cancer and other autoimmune diseases. However, it remains ver...
 (Total 109 words)
Alzheimer’s disease is a chronic disease that takes 10 to 20 years for the debilitating behavior of painful former’s cognitive function loss and memory loss. The treatments currently available are limited to treat only the symptoms of this disease that affect the patients of above 60 years age. A new research has found that Aducanumab is a human monoclonal antibody that can clear the brain amyloid plaques found in Alzheimer’s disease. It is also seen that complete removal of amyloid is also repo...
 (Total 106 words)
Alzheimer Disease is a chronic progressive deterioration of memory and functionality of the aging population. Its incidence will be increased over the year due to an increased aging population. Currently, there is no effective treatment or cure for this condition. It is interesting to know that a new human monoclonal antibody Aducanumab can potentially treat Alcheimer Disease. Aducanumab works by binding to amyloid plaques selectively, and remove the amyloid plaques by enabling microglial cells...
 (Total 124 words)